COMMUNIQUÉS West-GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/08/2026
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company [...]
Biodesix Announces Second Quarter 2026 Results and Highlights
05/08/2026
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Conference Call and [...]
Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
05/08/2026
Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc [...]
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
05/08/2026
Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases and that patients [...]
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
05/08/2026
EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) [...]
Pacific Health Care Organization, Inc. Reports its Second Quarter 2026 Financial Results
05/08/2026
Irvine, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on [...]
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
05/08/2026
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase [...]
Monthly information on share capital and company voting rights
05/08/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/08/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 août 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
STERIS Announces Financial Results for Fiscal 2027 First Quarter
05/08/2026
Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59 [...]
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
05/08/2026
– LOQTORZI ® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October [...]
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
05/08/2026
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz ® (aminolevulinic acid hydrochloride) Gel, [...]
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
05/08/2026
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 [...]
Pennant Reports Second Quarter 2026 Results
05/08/2026
Conference Call and Webcast scheduled for tomorrow, August 6, 2026 at 10:00 am MT EAGLE, Idaho, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
LifeMD Reports Second Quarter 2026 Results
05/08/2026
Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. [...]
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
05/08/2026
Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026 MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of [...]
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
05/08/2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations [...]
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
05/08/2026
Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash [...]
JellyBlue Launch 2026 New Advanced Gummies For Men's Performance And Vitality Support in the USA. JellyBlue Supplement Facts And ingredients Highlights,
05/08/2026
JellyBlue announces the launch of JellyBlue Gummies, a natural Supplement developed for adult men's health to support Performance, energy and Vitality. The new daily formula combines carefully selected ingredients with [...]

Pages